Bimosiamose

Drug Profile

Bimosiamose

Alternative Names: BIMO; Bimosiamose disodium; TBC 1269; TBC 1269z

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Revotar Biopharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Glycoconjugates; Hexanes; Skin disorder therapies; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Plaque psoriasis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Sep 2011 Final efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011)
  • 30 Mar 2011 Discontinued - Phase-I for Adult respiratory distress syndrome in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top